Description
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 6
Primary Industries
- Drugs
- Disease
- Therapeutic
- Pharmaceuticals
- Viral Infection
- Antibiotic
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 253916
The paternts are for 18-Membered Macrocycles And Analogs Thereof; Treatment of Diseases Associated With the Use of Antibiotics; Polymorphic Crystalline Forms Of Tiacumicin B; Compositions of Stable Tiacumicins; Method of Treating Clostridium Difficile-Associated DIARRHEA; Treatment Of Diseases Associated With The Use Of Antibiotics; Tiacumicin Production; and, Treatment of CDI patients with concomitant antibiotics, recurrence , and, virulent strains.
CDI shall mean Clostridium difficile infection in humans.
Clostridium difficile infection (CDI or C-dif) is a symptomatic infection due to the spore-forming bacterium, Clostridium difficile. Symptoms include watery diarrhea, fever, nausea, and abdominal pain.[1] It makes up about 20% of cases of antibiotic-associated diarrhea.
IPSCIO Record ID: 279361
US Patent No. 6,635,260 – Methods and compositions for prevention and treatment of Clostridium difficile-associated diseases
NTCD means that certain bacterium referred to as Non-Toxigenic Clostridium difficile.
Materials means A sample of each NTCD restriction endonuclease analysis (REA) type from REA groups M, T, C, P, S, and AP, which will specifically include types M3, M13, M23, and T7. All types will be provided in duplicate, one specimen in duplicate, one specimen in chopped meat broth and the second frozen at minus 70 degrees C in glycerol.
Clostridium difficile, also known as C. difficile or C. diff, is bacteria that can infect the bowel and cause diarrhoea. The infection most commonly affects people who have recently been treated with antibiotics.
IPSCIO Record ID: 237266
Licensor grants a nonexclusive license to use Licensor Know-how within the Territory for any purpose consistent with the rights and obligations contained in this Agreement.
Ramoplanin is a glycolipodepsipeptide antibiotic drug derived from strain ATCC 33076 of Actinoplanes.
Licensor is a pharmaceutical company interested in the identification and development of naturally produced compounds for the treatment of infectious diseases, and the commercialization of products based upon such compounds.
Licensor discovered and is developing a proprietary compound, Ramoplanin, and is currently conducting clinical trials in the U.S. of an oral formulation of Ramoplanin for the prevention of infectious diseases in patients carrying Vancomycin-resistant Enterococci ('VRE') and at risk of infection following chemotherapy or transplantation, with a view to registering a new pharmaceutical product for worldwide marketing under its trademark(s) and trade name(s).
Ramoplanin is in a Phase III clinical trial for the prevention of bloodstream infections caused by vancomycin-resistant enterococci, also known as VRE, and a Phase II clinical trial to assess the safety and efficacy of Ramoplanin to treat Clostridium difficile-associated diarrhea (CDAD).
If approved, Ramoplanin would be the first available antibiotic to prevent VRE bloodstream infections.
IPSCIO Record ID: 121
IPSCIO Record ID: 28765
Clostridium difficile is a species of Gram-positive spore-forming bacterium that is best known for causing antibiotic-associated diarrhea (AAD). While it can be a minor normal component of colonic flora, the bacterium is thought to cause disease when competing bacteria in the gut have been wiped out by antibiotic treatment.
IPSCIO Record ID: 273458
Licensor hereby grants to Licensee a worldwide, irrevocable, royalty-free, non-exclusive license, with the right to sublicense under the Licensor Licensed Know-how and Materials, to manufacture, Develop and Commercialize Bulk Compound, Compound, and Products; provided, however, that in the event that Licensor is required to pay any fees associated with Licensee’s use of any Licensor Licensed Know-how and Materials on or following the Effective Date, Licensor will notify Licensee of such fees and if Licensee agrees in writing to obtain such license, Licensor and Licensee will negotiate in good faith to determine the amount of royalty or other payment due to Licensor in consideration for the license granted.
Compound means the compound known as Ramoplanin, as described in IND Nos. 56,341 and 66,175. Ramoplanin is for the treatment or prevention of any human disease
The Assigned Property includes but not limited to the Assigned Patents, Assigned Know-how, Global Trademarks and Global Tradenames.
Patents include
US Application #08/993,729 (Grant #5925550) – Method for selectively increasing the ratio of single major components of antibiotic A/16686 complex.
US Application #08/444,808 (Grant #5539087) – Antibiotic A/16686 recovery process.
US Application #09/744247 (Grant #6720305B1) – Injectable formulations containing ramoplanin.
Global Trademarks and Global Tradenames include Aridro, Giraxa, Eridax, Kevrak, Nibaxa, Qrozon, Zarvic.
C. difficile is a spore-forming bacterium known to cause diarrhea and colitis. In the past, C. difficile-associated disease has been mainly a concern in patients who have had recent antibiotic therapy and/or are hospitalized.
